Search results
5 FDA decisions to watch in the third quarter
BioPharma Dive· 4 days agoMultibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach...
10 clinical trials to watch in the second half of 2024
BioPharma Dive· 6 days agoStudy results are expected for two closely watched obesity drugs, while key tests await for a...